ATE531808T1 - Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna - Google Patents

Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna

Info

Publication number
ATE531808T1
ATE531808T1 AT07000486T AT07000486T ATE531808T1 AT E531808 T1 ATE531808 T1 AT E531808T1 AT 07000486 T AT07000486 T AT 07000486T AT 07000486 T AT07000486 T AT 07000486T AT E531808 T1 ATE531808 T1 AT E531808T1
Authority
AT
Austria
Prior art keywords
hiv
recombinant cells
dna
triplex dna
vectors
Prior art date
Application number
AT07000486T
Other languages
English (en)
Inventor
Pierre Charneau
Veronique Zennou
Francoise Pflumio
Aude Sirven
Kupperschmitt Anne Dubart
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE531808T1 publication Critical patent/ATE531808T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07000486T 1999-10-12 2000-10-10 Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna ATE531808T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15838799P 1999-10-12 1999-10-12

Publications (1)

Publication Number Publication Date
ATE531808T1 true ATE531808T1 (de) 2011-11-15

Family

ID=22567880

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00969534T ATE351916T1 (de) 1999-10-12 2000-10-10 Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten
AT07000486T ATE531808T1 (de) 1999-10-12 2000-10-10 Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00969534T ATE351916T1 (de) 1999-10-12 2000-10-10 Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten

Country Status (15)

Country Link
US (7) US8093042B2 (de)
EP (2) EP1792997B1 (de)
JP (1) JP4436024B2 (de)
CN (2) CN101363029B (de)
AT (2) ATE351916T1 (de)
AU (2) AU784910B2 (de)
CA (1) CA2382832C (de)
CY (2) CY1106513T1 (de)
DE (1) DE60033045T2 (de)
DK (2) DK1224314T3 (de)
ES (2) ES2377721T3 (de)
HK (2) HK1050210B (de)
IL (3) IL148900A0 (de)
PT (2) PT1792997E (de)
WO (1) WO2001027304A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
DE69941703D1 (de) 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
CA2382832C (en) 1999-10-12 2012-06-26 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
AU2002327412A1 (en) 2001-08-02 2003-02-17 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
EP1438075A4 (de) 2001-10-02 2006-04-19 Inst Clayton De La Rech Verfahren und zusammensetzungen in verbindung mit lentiviralen vektoren mit begrenzter expression und ihre anwendungen
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
EP1748067A1 (de) 2005-07-29 2007-01-31 Institut Pasteur Polynukleotide, die für MHC Klasse I-beschränkte Epitope der hTERT, Analoge und Polyepitope kodieren
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
EP3293266A1 (de) 2007-05-04 2018-03-14 University Health Network Il-12-immuntherapie gegen krebs
EP2385107B1 (de) 2010-05-03 2016-08-24 Institut Pasteur Auf Lentivirusvektor basierende immunologische Verbindungen gegen Malaria
EP2666477A1 (de) 2012-05-23 2013-11-27 Theravectys Lentivirale Vektoren mit einem MHC-Klasse-I-Promotor
US9403880B2 (en) 2010-11-26 2016-08-02 Institut Pasteur Identification of a human gyrovirus and applications
ES2651922T3 (es) 2011-11-08 2018-01-30 Institut Pasteur Polipéptidos de afinidad elevada para MAST2 y usos de los mismos
EP2788477A2 (de) 2011-12-07 2014-10-15 Institut Pasteur Identifizierung des porcinen parecho-like virus und anwendungen
US20150182617A1 (en) 2012-07-25 2015-07-02 Theravectys Glycoproteins for pseudotyping lentivectors
AU2014338555B2 (en) * 2013-10-24 2019-10-10 Fondazione Telethon Method
EP3031923A1 (de) 2014-12-11 2016-06-15 Institut Pasteur Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
US20180022781A1 (en) 2015-02-13 2018-01-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
FR3044017B1 (fr) 2015-11-24 2019-05-03 Glaxosmithkline Intellectual Property Development Limited Procede de transfection transitoire pour la production retrovirale
EP3211003A1 (de) 2016-02-24 2017-08-30 Institut Pasteur T-zell-rezeptoren aus dem hiv-spezifischen repertoire, mittel zu deren herstellung und therapeutische verwendung davon
EP3443001A4 (de) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Regulierte bioschaltkreissysteme
ES2885833T3 (es) 2016-04-20 2021-12-15 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Composición y métodos para potenciar la expresión génica de PKLR
AU2017281065B2 (en) * 2016-06-22 2022-10-27 Yale University Mechanism based quality control for botanical medicine
EP3357504A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Funktionelles screening von antigenen polypeptiden verwendung zur identifizierung von antigenen zur anregung einer schützenden immunantwort und zur auswahl von antigenen mit optimaler schutzwirkung
EP3357506A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Mehrere malaria-prä-erythrozyten-antigene und deren verwendung bei der auslösung einer schützenden immunantwort in einem wirt
BR112020007444A2 (pt) 2017-10-16 2020-10-20 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. vetores lentivirais para a liberação de pklr para tratar deficiência de piruvato quinase
JP2021520853A (ja) 2018-04-12 2021-08-26 ウモジャ バイオファーマ， インコーポレイテッド ウイルスベクター及びパッケージング細胞株
EP3796893A1 (de) 2018-05-23 2021-03-31 Modernatx, Inc. Dna-zuführung
US20220017920A1 (en) 2018-11-21 2022-01-20 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
AU2020366206A1 (en) 2019-10-16 2022-06-02 Umoja Biopharma, Inc. Retroviral vector for universal receptor therapy
CN117120085A (zh) 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
WO2022015955A1 (en) 2020-07-16 2022-01-20 Umoja Biopharma, Inc. Gated adapter targeting receptor
BR112023001852A2 (pt) 2020-08-07 2023-02-23 Spacecraft Seven Llc Terapia gênica com placofilina-2 (pkp2) usando vetor de aav
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
EP3984548A1 (de) 2020-10-16 2022-04-20 Institut Pasteur Generation von lentiviralen vektoren, die es ermöglichen, antigene zum mhc-ii-weg zu leiten und cd4+- und cd8+-t-zellantworten als immunantwort in einem wirt zu induzieren
WO2022109162A1 (en) 2020-11-20 2022-05-27 Umoja Biopharma, Inc. Vector system for delivery of multiple polynucleotides and uses thereof
BR112023018329A2 (pt) 2021-03-12 2023-10-10 Pasteur Institut Genoma de vetor lentiviral recombinante, plasmídeo de dna, partícula de vetor lentiviral recombinante, célula hospedeira, composição farmacêutica e método para a preparação de partículas de vetor lentiviral
WO2023115049A1 (en) 2021-12-17 2023-06-22 Umoja Biopharma, Inc. Cytotoxic innate lymphoid cell and uses thereof
WO2023225569A1 (en) 2022-05-17 2023-11-23 Umoja Biopharma, Inc. Manufacturing viral particles
WO2023240282A1 (en) 2022-06-10 2023-12-14 Umoja Biopharma, Inc. Engineered stem cells and uses thereof
WO2024084041A2 (en) 2022-10-21 2024-04-25 Institut Pasteur Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host
WO2024098038A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Polynucleotide construct and related viral vectors and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2000506727A (ja) * 1996-03-05 2000-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
CA2286819A1 (en) 1997-04-17 1998-10-22 Flossie Wong-Staal Use of lentiviral vectors for antigen presentation in dendritic cells
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7622300B2 (en) 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9825524D0 (en) * 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
DE69941703D1 (de) 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
CA2382832C (en) 1999-10-12 2012-06-26 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
CN101363029A (zh) 2009-02-11
EP1792997A1 (de) 2007-06-06
US8512993B2 (en) 2013-08-20
ES2377721T3 (es) 2012-03-30
US20150011006A1 (en) 2015-01-08
CA2382832A1 (en) 2001-04-19
ES2280250T3 (es) 2007-09-16
IL148900A0 (en) 2002-09-12
US20180346928A1 (en) 2018-12-06
WO2001027304A2 (en) 2001-04-19
US8093042B2 (en) 2012-01-10
JP4436024B2 (ja) 2010-03-24
HK1109167A1 (en) 2008-05-30
AU2006233199B2 (en) 2009-07-23
US20120122963A1 (en) 2012-05-17
DK1224314T3 (da) 2007-05-21
EP1792997B1 (de) 2011-11-02
PT1224314E (pt) 2007-04-30
DK1792997T3 (da) 2012-01-30
IL198076A (en) 2011-12-29
CY1112430T1 (el) 2015-12-09
US8512994B2 (en) 2013-08-20
WO2001027304A3 (en) 2001-11-29
CY1106513T1 (el) 2012-01-25
PT1792997E (pt) 2012-02-02
HK1050210A1 (en) 2003-06-13
US9238824B2 (en) 2016-01-19
DE60033045D1 (de) 2007-03-08
CN1402793A (zh) 2003-03-12
AU2006233199A1 (en) 2006-11-23
CN101363029B (zh) 2016-01-13
US20070224679A1 (en) 2007-09-27
AU7921700A (en) 2001-04-23
EP1224314A2 (de) 2002-07-24
EP1224314B1 (de) 2007-01-17
DE60033045T2 (de) 2007-11-08
ATE351916T1 (de) 2007-02-15
US20120122204A1 (en) 2012-05-17
CN100425702C (zh) 2008-10-15
CA2382832C (en) 2012-06-26
US20190119699A1 (en) 2019-04-25
IL148900A (en) 2009-11-18
AU784910B2 (en) 2006-07-27
US20150191745A1 (en) 2015-07-09
US10407695B2 (en) 2019-09-10
HK1050210B (zh) 2007-08-24
JP2003511083A (ja) 2003-03-25

Similar Documents

Publication Publication Date Title
ATE531808T1 (de) Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna
JP2020100622A5 (de)
NO20015587D0 (no) Ekspresjon og eksport av interferon-<alfa> proteiner som Fc- fusjonsproteiner
WO2002014358A3 (en) Novel secreted proteins and their uses
ATE318896T1 (de) Rekombinante rna-replikase von hepatitis-c-virus
WO2000053788A3 (en) Compositions and methods for recombinant adeno-associated virus production
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
DE60044754D1 (de) Trans-lentivirales Vektor System
WO2004005467A3 (en) Expression of human interferon in transgenic chloroplasts
DE69941596D1 (de) Schweineadenovirus vektor
FI885296A (fi) Rekombinant hiv-2 polypeptid.
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
ATE166390T1 (de) Anti-katze immundefiziensvirus (fiv) impfstoffe
FR2607518B1 (fr) Vecteur viral et adn recombinant codant pour la proteine p25 du virus agent causal du s.i.d.a., culture cellulaire infectee, proteine obtenue, vaccin et anticorps obtenus
WO2002016578A3 (en) Secreted proteins and methods of using same
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
RU2346044C2 (ru) ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pBMC-gp140(A)-hum
RU2345138C2 (ru) ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК р-ВМС-gag(A)-hum ДЛЯ ЭКСПРЕССИИ БЕЛКА р55 ВИЧ-1 В КЛЕТКАХ ЭУКАРИОТ
WO2000053789A3 (de) Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen
WO2002068464A3 (de) Fusionsprotein zum blocken des hiv nef-proteins
WO2002000709A3 (en) Cerebellin homologous polypeptides and therapeutic uses thereof
CA2426348A1 (en) Retrovirus isolated from humans
TH13136EX (th) แอนติเจนของ hiv